Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-03
2007-07-03
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S326000, C514S318000, C514S275000, C544S331000, C546S193000, C546S208000, C548S517000
Reexamination Certificate
active
11036258
ABSTRACT:
The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
REFERENCES:
patent: 5691356 (1997-11-01), Das et al.
patent: 6011155 (2000-01-01), Villhauer
patent: 6172081 (2001-01-01), Damon
patent: 6395767 (2002-05-01), Robl et al.
patent: 6544992 (2003-04-01), Dhanak et al.
patent: 93/01167 (1993-01-01), None
patent: 07/40832 (1997-11-01), None
patent: 01/34594 (2001-05-01), None
patent: 01/68603 (2001-09-01), None
patent: 01/96295 (2001-12-01), None
patent: 02/30890 (2002-04-01), None
patent: 03/084940 (2003-10-01), None
patent: 03/092605 (2003-11-01), None
patent: 2004/016587 (2004-02-01), None
Weber, A. E. J. Med. Chem. 2004, 47, 4135-4141.
Ahrén, B., “Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes”,BioEssays20(8):642-651 (1998).
Ahrén, B., “Inhibition of Dipeptidyl Peptidase IV Improves Metaboli Control Over a 4-Week Study Period in Type 2 Diabetes”,Diabetes Care,25(5):869-875 (2002).
Barreto-Filho, J.A.S., et al., “Familial Isolated Growth Hormone Deficiency Is Associated with Increased Systolic Blood Pressure, Central Obesity, and Dyslipidemia”,The Journ of Clin Endocrin&Metab,87(5):2018-2023 (2002).
Colao, A., et al., “The Cardiovascular Risk of Adult GH Deficiency (GHD) Improved after GH Replacement and Worsened in Untreated GHD: LA 12-Month Prospective Study”,The Journ of Clin Endocrin&Metab.,87(3):1088-1093 (2002).
Cornish-Bowden, A., “Fundamentals of Enzyme Kinetics”,Rev Ed.,(1995).
Coutts, Simon, J., “Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. 1. Variation of the P2Position of Xaa-boroPro Dipeptides”,J Med Chem,39:2087-2094 (1996).
Deacon, C.F., et al., “Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH sub 2-Terminus in Type II Diabetic Patients and in Healthy Subjects”,Diabetes Care Inc.,44(9):1126-2231 (1995).
Deacon, C. F., “Dipeptidyl Peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig”,Diabetes,vol. 47:764-769, (May 1998).
Drucker, D.J., “Glucagon-Like Peptides”,Diabetes Care.,47(2):159-169 (1998).
Flint, A., et al., “Glucagon-like Peptide 1 Promotes Satiety and Suppresses Energy Intake in Humans”,J Clin Invest,101(3):515-520 (1998).
Götherström, G., et al., “A Prospective Study of 5 Years of GH Replacement Therapy in GH-Deficient Adults; Sustained Effects on Body Compositoin, Bone Mass, and Metabolic Indices”,Journ of Clin Endocrin&Metab,96(10):4657-4665 (2001).
Greene, T.W., “Proctection Groups in Organic Synthesis”,Third Ed,(1999).
Gutniak, M.K., et al., “Antidiabetogenic action of glucagons-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes”,Journ of Int Med,250:81-87 (2001).
Gutzwiller, J-P., et al., “Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2”,Lam J Physiol,276:R1541-1544 (1999).
Hughes, T.E., “1-2-5 Cyanopyridin-2-yl) amino ethyl amino acetyl-2-cyano-(S) pyrrolidine), a Slow Binding Inhibitor of Dipeptidyl Peptidase IV”, Biochemistry 1999, vol. 38, pp. 11597-11603.
Johansson, J-O., “Growth Hormone-Deficient Adults Are Insulin-Resistant”,Metabolism,44(9):1126-1129 (1995).
Johannsson, G., et al., “Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoportei Metabolism, and Reduces Diastolic Blood Pressure”,Journ of Clin Endocrin&Metab,82(3):727-734 (1997).
Johannsson, G. and Bengtsson, B-A., “Growth hormone and the metabolic syndrome”,J Endocrinol Invest,22:41-46 (1999).
Juntti-Berggren, L., et al., “The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients”,Diabetes Care.,19(11):1200-1206 (1996).
Knudsen, L.B., and Pridal, L., “Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagons-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor”,Eur Journ of Pharmacology,318:429-435 (1996).
Kubial, T.M., et al., “In Vitro Metabolic Degradation of a bovine Growth Hormone-Releasing Factor Analog LEU27-bGRF-(1-29)NH2in Bovine and Porcine Plasma”,Durg Metab and Disp,17(4):393-397 (1989).
Li, J., et al., “Aminoacylpyrrolidine-2-nitriles: Potent and Stable Inhibitors of Dipeptidyl-Peptidase IV (CD 26)”,Arch of Biochem and Biophysics,323(1):148-154 (1995).
Mentlein, R., et al., “Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagons-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum”,Eur J Biochem,214:829-835 (1993).
Mentlein, R., “Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides”,Reg Peptides,85:9-24 (1999).
Näslund, E., et al., “Glucagon-like peptide 1 increases the period of posprandial satiety and slows gastric emptying in obese men1-3”,Am J Clin Nutr,68:525-530 (1998).
Nauck, M.A., et al., “Glucagon-Like Peptide 1 and its Potential in the Treatment of Non-Insulin-Dependent Diabetes Mellitus”,Horm Metab Res.,29:411-416 (1997).
Ohnuma, K., “Soluble CD26/Dipeptidyl Peptidase IV Induces T Cell Proliferation through CD86 Up-Regulation on APCs1”,J. of Immunology,167(12):6745-6755 (2001).
Ohtsuki, T., et al., “Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1α by CD26/dipeptidyl peptidase IV”,FEBS Letters,431:236-240 (1998).
Proost, P., et al., “Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1α”,FEBS Letters,432:73-76 (1998).
Rachman, J., et al., “Near-normalisation of diurnal glucose concentrations by continuous administration of glucagons-like peptide-1 (GLP-1) in subjects with NIDDM”,Diabetologia,40:205-211 (1997).
Reaven, G.M., “Pathophysiology of Insulin Resistance in Human Disease”,Physiol Re.,75:473-486 (1995).
Shioda, T., et al., “Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1α (SDF-1α) and SDF-1β are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage”,Proc Natl Acad Sci, USA,95:6331-6336 (1998).
Tanaka, T., “The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity”,Proc Natl Acad Sci USA,90:4586-4590 (1993).
Tanaka, T., et al., “Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV”,Proc Natl Acad Sci USA,91:3082-3086 (1994).
Toft-Nielsen, , et al., “Continuous Subcutaneous Infusion of Glucagon-Like Peptide 1 Lowers Plasma Glucose and Reduces Appetite in Type 2 Diabetic Patients”,Diabetes Care,22(7):1137-1143 (1999).
Villhauer, Edwin, B., “1-3-Hydroxy-1-adamantyl)amino] acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties,”J. Med. Chem.,46:2774-2789 (2003).
Zander, M., et al., “Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes”,Diabetes Care,24(4):720-725 (2001).
Djuric Stevan W.
Kopecka Hana A.
Li Xiaofeng
Longenecker Kenton L.
Madar David J.
Abbott Laboratories
Corbin Johanna M.
Nolan Jason M.
Parial Andrew M.
LandOfFree
Pharmaceutical compositions as inhibitors of dipeptidyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions as inhibitors of dipeptidyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions as inhibitors of dipeptidyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3744802